BRAF and metastatic neoplasm: Critically however, while both BRAF mutation and the pred-BRAFm signatures could identify subgroups of patients with poorer OS after relapse (i.e. when the patient had progressed to stage IV metastatic disease), the rates of disease relapse in these subgroups were not significantly different to BRAFWT and pred-BRAFwt disease.